查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612272

异位性皮肤炎市场：按药物类别、给药途径、分销管道划分 - 全球预测 2025-2030

Atopic Dermatitis Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable, Oral, Topical), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年异位性皮肤炎市值为63.8亿美元，预计到2024年将达到67.4亿美元，复合年增长率为5.88%，预计到2030年将达到95.3亿美元。

异位性皮肤炎 (AD) 是一种慢性发炎皮肤病，其特征是剧烈搔痒和復发性湿疹皮损，影响着世界上很大一部分人口。这种疾病的范围超出了皮肤病学范围，还包括过敏、免疫学，甚至由于其心理影响而包括心理健康。随着盛行率的增加，市场需求出现，对有效治疗的需求迅速增加。因此，AD 治疗已成为皮肤科和药物组合的重要组成部分。它们的应用范围从外用和口服药物到生技药品和单株抗体等新治疗剂。最终用户主要是医疗保健提供者、皮肤科诊所、研究机构以及因 AD 导致生活品质问题的患者。市场开拓受到医疗保健成本上升、意识提高以及药物开发（包括个人化医疗和生技药品）进步的影响。对非类固醇治疗和更安全的长期控制方案的未满足需求存在着巨大的机会。与研究机构合作探索遗传起源和环境触发因素提供了潜在的成长途径。值得注意的机会包括利用数位健康工具进行远端监控和管理，以确保患者遵守治疗方法。另一方面，其局限性包括先进治疗的高成本、保险范围的问题以及与长期使用类固醇相关的副作用。新疗法的监管障碍以及学名药的竞争也带来了挑战。需要创新的领域包括新药物传输系统的开发、微生物标靶治疗方法的探索以及特异性针对潜在发炎途径的生物製药的进展。市场充满活力且竞争激烈，保持领先需要不断的研究和发展。公司正在专注于结合皮肤病学、免疫学、数位健康等领域的多学科方法，不仅可以缓解症状，还可以有效地解决疾病的根源，提高患者的生活品质和业务成长。方案来改善。

主要市场统计
基准年[2023] 63.8亿美元
预计年份 [2024] 67.4亿美元
预测年份 [2030] 95.3亿美元
复合年增长率（%） 5.88%

市场动态：快速发展的异位性皮肤炎市场的关键市场洞察

异位性皮肤炎市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 异位性皮肤炎的发生率增加
    • 食物过敏的盛行率不断增加，加剧了异位性皮肤炎
    • 保护皮肤屏障的新型保湿剂、生技药品、补脂外用药的开发
  • 市场限制因素
    • 治疗药物高成本
  • 市场机会
    • 治疗方法意识不断增强
    • 促进各开发中国家获得治疗的机会
  • 市场挑战
    • 与药物相关的副作用

波特五力：驾驭异位性皮肤炎市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解异位性皮肤炎市场的外部影响

外部宏观环境因素在塑造异位性皮肤炎市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解异位性皮肤炎市场的竞争状况

对异位性皮肤炎市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵异位性皮肤炎市场供应商的绩效评估

FPNV定位矩阵是评估异位性皮肤炎市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了异位性皮肤炎市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对异位性皮肤炎市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 异位性皮肤炎的发生率增加
      • 食物过敏和严重异位性皮肤炎的增加
      • 开发保护皮肤屏障的新型保湿剂、生技药品及局部补脂药物
    • 抑制因素
      • 治疗费用上涨
    • 机会
      • 提高对该疾病治疗方法可用性的认识
      • 扩大各个新兴国家获得治疗的机会
    • 任务
      • 与药物使用相关的副作用
  • 市场区隔分析
    • 药物类别：抑制剂的巨大优势，疗效更高，副作用最小
    • 分销管道：由于宅配服务和折扣，网路药局越来越受欢迎
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的异位性皮肤炎市场

  • 生物製药
  • Calcineurin抑制剂
  • 皮质类固醇
  • PDE-4抑制剂

第七章 异位性皮肤炎市场：依给药途径

  • 可注射的
  • 口服
  • 话题

第 8 章 异位性皮肤炎市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美异位性皮肤炎市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区异位性皮肤炎市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲异位性皮肤炎市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 强生公司透过策略收购 Proteologics 加强异位性皮肤炎和气喘的治疗选择
    • 礼来公司的 lebrikizumab 对患有异位性皮肤炎的有色人种皮肤有效
    • Glenmark 和辉瑞在印度推出新的异位性皮肤炎治疗方法
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma SA
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
  • Meda AB
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-FE70EC183B6D

The Atopic Dermatitis Market was valued at USD 6.38 billion in 2023, expected to reach USD 6.74 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 9.53 billion by 2030.

Atopic dermatitis (AD), a chronic inflammatory skin disease characterized by intense itching and recurrent eczematous lesions, affects a significant portion of the population globally. The condition's scope extends beyond dermatology, impacting allergology, immunology, and even mental health due to its psychological effects. Market necessity arises as prevalence increases, and the requirement for effective treatment catapults. This makes AD treatment an indispensable part of dermatological and pharmaceutical portfolios. Applications span from topical and oral pharmaceuticals to biologics and emerging therapies like monoclonal antibodies. End-users primarily include healthcare providers, dermatology clinics, researchers, and patients struggling with quality-of-life issues due to AD. Market growth is influenced by increased healthcare expenditure, rising awareness, and advancements in drug development, including personalized medicine and biologics. A significant opportunity lies in the unmet needs for non-steroidal treatments and safer, long-term control options. Partnerships with research institutes to explore genetic origins and environmental triggers offer potential growth pathways. A notable opportunity involves leveraging digital health tools for remote monitoring and management, ensuring patient adherence to treatment regimens. Conversely, limitations include the high cost of advanced treatments, insurance coverage challenges, and adverse side effects associated with long-term steroid use. Regulatory hurdles for new therapies also pose a challenge, coupled with competition from generic products. Areas ripe for innovation include the development of new drug delivery systems, exploration of microbiome-targeted therapies, and advances in biologics that specifically target underlying inflammatory pathways. The market presents a dynamic and competitive landscape, with continuous research and development required to stay ahead. Companies should focus on multidisciplinary approaches, incorporating insights from dermatology, immunology, and digital health to craft holistic solutions that not only alleviate symptoms but address the roots of the disease efficiently, enhancing patient quality of life and business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 6.38 billion
Estimated Year [2024] USD 6.74 billion
Forecast Year [2030] USD 9.53 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atopic Dermatitis Market

The Atopic Dermatitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of atopic dermatitis
    • Growing prevalence of food allergies intensifying atopic dermatitis
    • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Rising awareness regarding the availability of treatments for the disease
    • Growing access to treatment in various developing countries
  • Market Challenges
    • Adverse effects associated with the use of medication

Porter's Five Forces: A Strategic Tool for Navigating the Atopic Dermatitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atopic Dermatitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atopic Dermatitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atopic Dermatitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atopic Dermatitis Market

A detailed market share analysis in the Atopic Dermatitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atopic Dermatitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atopic Dermatitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atopic Dermatitis Market

A strategic analysis of the Atopic Dermatitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and PDE-4 Inhibitor.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of atopic dermatitis
      • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
      • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
      • 5.1.3.2. Growing access to treatment in various developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the use of medication
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Significant benefits of inhibitors with higher efficacy and minimal side effects
    • 5.2.2. Distribution Channel: Growing preferences for online pharmacies owing to home delivery services and discounts
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Atopic Dermatitis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Calcineurin Inhibitors
  • 6.4. Corticosteroids
  • 6.5. PDE-4 Inhibitor

7. Atopic Dermatitis Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Atopic Dermatitis Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Atopic Dermatitis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Atopic Dermatitis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Atopic Dermatitis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Johnson & Johnson's Strategic Acquisition of Proteologix to Enhance Atopic Dermatitis and Asthma Treatment Options
    • 12.3.2. Eli Lilly's Lebrikizumab Demonstrates Efficacy in Skin of Color for Atopic Dermatitis
    • 12.3.3. Glenmark and Pfizer Introduce New Atopic Dermatitis Treatment in India
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. Bausch Health Companies Inc.
  • 4. Bayer AG
  • 5. Biofrontera AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Galderma S.A.
  • 10. GlaxoSmithKline PLC
  • 11. LEO Pharma A/S
  • 12. Meda AB
  • 13. Mylan N.V.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc
  • 17. Sanofi S.A.
  • 18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ATOPIC DERMATITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ATOPIC DERMATITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATOPIC DERMATITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PDE-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023